Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management

(2016) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea

(2016) Genevieve Douglas et al.   LEUKEMIA & LYMPHOMA

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience

(2016) K Begna et al.   Blood Cancer Journal

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

(2014) Alberto Alvarez-Larrán et al.   ANNALS OF HEMATOLOGY

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

(2013) G. Barosi et al.   BLOOD

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

(2010) Juan-Carlos Hernández-Boluda et al.   BRITISH JOURNAL OF HAEMATOLOGY